The TOP20 market for tens of billions of cold Chinese patent medicines is released! 2 billion large varieties lead 6 exclusive lists

At the time when the common cold is high, a new breakthrough in the field of Chinese patent medicines for colds-the first category 1 innovative drug was approved for listing
.

Ten billion cold Chinese patent medicine market! China Resources and Yiling lead

The cold is the most common disease, and it is even more "presumptuous" in the cold winter
.

According to the latest data from Minet.
com, in 2020, the sales of Chinese patent medicines for colds in physical pharmacies in cities in China will exceed 11 billion yuan.
Sales in 2021 are expected to fall by 8.
51% year-on-year
.

Sales of proprietary Chinese medicines for colds in physical pharmacies in cities in China (unit: ten thousand yuan)

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

From the perspective of manufacturers, the top 5 manufacturers in the retail market of cold Chinese patent medicines in 2021 are expected to be China Resources Sanjiu Pharmaceutical, Shijiazhuang Yiling Pharmaceutical, Yunnan Baiyao Group, China Resources Sanjiu (Chenzhou) Pharmaceutical, and Guangzhou Xiangxue Pharmaceutical
.

Market structure of TOP5 manufacturers of cold proprietary Chinese medicines in physical pharmacies in cities in China

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

China Resources Sanjiu Pharmaceutical has been ranked No.
1 for many consecutive years, and its market share is expected to rise to 23.
95% in 2021.
Although Shijiazhuang Yiling Pharmaceutical is the second in the millennium, its sales have grown rapidly in recent years and its market share has exceeded 10%
.

TOP20 Chinese patent medicines for colds are released! One billion magic medicine Waterloo?

Top 20 Chinese patent medicine products for colds in physical pharmacies in cities in China

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

In 2021, among the TOP20 cold TCM products in physical pharmacies in Chinese cities, 17 products are expected to have sales of more than 100 million yuan; Ganmaoling granules is still the only variety with sales exceeding 2 billion yuan, and it is expected to increase by more than 10%; even After the sales of Huaqingwen Capsule and Shuanghuanglian Oral Liquid exceed 1 billion yuan in 2020, they are expected to decline in 2021
.

Six of the 20 products are exclusive varieties, namely Lianhua Qingwen Capsules and Lianhua Qingwen Granules of Yiling Pharmaceutical, Antiviral Granules of Sichuan Everbright Pharmaceutical, Four Seasons Antiviral Mixture of Shaanxi Haitian Pharmaceutical, Yunnan Baiyao Group Shangfengting Capsules and Jinlian Qingre Granules of Ningxia Qiyuan National Medicine
.

From the perspective of sales growth rate, the TOP20 products rose and fell by half
.

Sales of six products fell by more than 20%, mainly for drugs included in the "Drug List for Real-Name Registration Reporting During the Epidemic"
.

Sales of Shuanghuanglian Oral Liquid at Terminals of Entity Pharmacies in Chinese Cities (Unit: Ten Thousand Yuan)

Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern

The first class 1 new Chinese medicine approved! Kangyuan grabs the tens of billions market

On November 15, Kangyuan Pharmaceutical issued an announcement stating that the company’s Yinqiao Qingre tablets were approved by the State Drug Administration for the treatment of exogenous wind-heat common colds
.

The prescription of Yinqiao Qingre Tablets is based on the famous prescription "Yinqiao Baidu Decoction" for febrile diseases by Professor Wang Yongyan, an academician of the Chinese Academy of Engineering.
, And has the therapeutic effects of clearing lung heat, relieving throat pain, purging fire and detoxification, relieving cough and resolving phlegm
.

The approval of Yinqiao Qingre Tablets has further enriched the important product line of Kangyuan Pharmaceutical-the product echelon in the field of anti-infection
.

Since the beginning of this year, a total of 6 new Chinese medicines have been approved for marketing in China, including Yinqiao Qingre Tablets from Kangyuan Pharmaceutical, Yizhi Anshen Tablets from Yiling Pharmaceutical, Yiqi Tongqiao Pills from Tianjin Dongfang Huakang Pharmaceutical, and Guangdong Yifang Pharmaceutical Huashibaidu Granules, Xuanfeibaidu Granules of Shandong Buchang Pharmaceutical, Qingfei Paidu Granules of China Academy of Chinese Medical Sciences
.

New Chinese medicines approved for marketing since 2021

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Kangyuan Pharmaceutical’s Yinqiao Qingre Tablets are not only the first class 1.
1 Chinese medicine innovative drug approved for marketing since the implementation of the new Chinese medicine registration classification on July 1, 2020, but also after the approval of Jinhua Qinggan Granules in 2016, it has been in the past 5 years.
The first innovative Chinese medicine for colds approved for marketing
.

It is worth noting that there are two other cold Chinese patent medicines under review, including Shenzhen Sanshun Pharmaceutical’s Caohong Capsules and Tasly’s Xiao Chaihu Decoction Dropping Pills
.

Data source: Mi Nei.
com database, company announcement

Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.